nash

Anti-NASH agent 2 (compound 21) is an inhibitor of neolipogenesis activity and α-SMA gene expression. It improves hepatic steatosis, edema, inflammatory infiltration, and liver fibrosis in NASH mouse models.

Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α δ agonist aimed at treating nonalcoholic steatohepatitis (NASH). At dosages of 3-10 mg kg over four weeks, this compound ameliorates hyperlipidemia, liver fat degeneration, and inflammation in a methionine-choline deficiency (MCD)-induced NASH mouse model, exhibiting minimal hepatotoxicity while providing substantial hepatic protection [1].

Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hypertriglyceridemia, lowers triglycerides, and may be useful in studies of liver fibrosis and atherosclerosis.

INT-767 is a potent farnesoid X receptor (FXR) TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis.

Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.Berberine ursodeoxycholate has a wide range of metabolic activity and significantly reduces liver fat content. Berberine ursodeoxycholate has been used in studies of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.

Glycolithocholic acid (Lithocholic acid glycine conjugate) is a glycine conjugate of lithocholic acid.

Aramchol (C20-FABAC), also known as arachidyl amido cholanoic acid, is a conjugate of arachidic acid and cholic acid. It reduces ex vivo cholesterol crystallization in native human bile and dissolves pre-formed cholesterol crystals in a dose-dependent manner.

Gardenoside has hepatoprotective, pain‑relieving, and anti-mastitis effects. it may be a potential therapeutic herb against NASH by suppressed supernatant inflammatory cytokine production and intracellular NFkB activity. Gardenoside may be considere

Efinopegdutide (JNJ-64565111) is a potent dual agonist for the glucagon-like peptide-1 (GLP-1) and glucagon receptors (GluR), demonstrating efficacy in activating both receptors, with potential applications in the research of nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-71 (Compound 149), an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), displays potent activity with an IC 50 value of ≤ 0.1 μM against estradiol. This compound is applicable in the study of various disorders including liver diseases, metabolic diseases, and cardiovascular conditions such as NAFLD or NASH, in addition to drug-induced liver injury (DILI) [1].

HSD17B13-IN-28 (compound 47) is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), with an IC50 of < 0.1 μM using estradiol as a substrate. HSD17B13-IN-28 plays an important role in nonalcoholic fatty liver diseases (NAFLDs), including NASH (nonalcoholic steatohepatitis) [1].

HSD17B13-IN-32 (Compound 67) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤0.1 μM for estradiol. It can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) [1].

HSD17B13-IN-17 (compound 9) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). It demonstrates inhibitory efficacy with IC50 values of ＜0.1 μM for estradiol and ＜1 μM for Leukotriene B3 as substrates. This compound is significant in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-19 (compound 16) acts as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values under 0.1 μM and under 1 μM when using estradiol and Leukotriene B3 as substrates, respectively. This compound is crucial in the treatment of nonalcoholic fatty liver diseases (NAFLDs), such as nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-40 (compound 6) serves as a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM using estradiol as substrates. This compound is significant in the treatment of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-52 (Compound 84), an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibits potent activity with an IC50 value of ≤ 0.1 μM against estradiol. This compound is applicable in the research of various health conditions including liver, metabolic, and cardiovascular diseases, specifically NAFLD, NASH, and drug-induced liver injury (DILI) [1].

HSD17B13-IN-42 (compound 10) is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), with an IC50 of < 0.1 μM using estradiol as substrates. HSD17B13-IN-42 plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) [1].

HSD17B13-IN-30 (compound 64) serves as a potent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), exhibiting an IC 50 value of less than 0.1 μM? with estradiol? as substrates. This compound is significantly implicated in the management of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH) [1].

HSD17B13-IN-55 (Compound 167) serves as an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC 50 value of ≤ 0.1 μM against estradiol. This compound is particularly useful in research related to liver, metabolic, and cardiovascular diseases including NAFLD, NASH, and drug-induced liver injury (DILI) [1].

HSD17B13-IN-57 (Compound 93) acts as an inhibitor targeting hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC 50 of ≤ 0.1 μM against estradiol. This compound is applicable in the study of various health conditions, including liver, metabolic, and cardiovascular diseases—specifically NAFLD, NASH—and drug-induced liver injury (DILI) [1].

HSD17B13-IN-12 (Compound 3), functioning as an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibits potent activity with an IC 50 value of ≤ 0.1 μM against both leukotriene B3 and estradiol. This compound is applicable in studying various conditions including liver diseases, metabolic disorders, and cardiovascular diseases like NAFLD or NASH, as well as drug-induced liver injury (DILI) [1].

ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)

A3051, is a robust and orally active inhibitor of CXXC5-DVL with an IC 50 of 63.06 nM. Its applications include research into phenotypes associated with obesity, diabetes, and NASH that are induced by high fat diet (HFD) and methionine-choline deficient diet (MCD).

DRX-065 is a stabilized and deuterated R-enantiomer of pioglitazone. DRX-065 has pharmacological properties desirable for the treatment of NASH (mitochondrial function modulation, non-steroidal anti-inflammatory effects, and glucose lowering effects) with